Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

SPERO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm

Newsfile June 1, 2020

Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

GlobeNewswire June 1, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2020

SPERO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm

GlobeNewswire May 28, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Spero Therapeutics, Inc. - SPRO

GlobeNewswire May 27, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO

ACCESSWIRE IA May 25, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Spero Therapeutics, Inc. - SPRO

GlobeNewswire May 13, 2020

SPRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm

ACCESSWIRE IA May 12, 2020

Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update

GlobeNewswire May 8, 2020

Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection

GlobeNewswire May 5, 2020

Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020

GlobeNewswire May 4, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 30, 2020

Spero Announces Appointment of Scott Jackson to its Board of Directors

GlobeNewswire April 16, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 31, 2020

Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update

GlobeNewswire March 16, 2020

Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

GlobeNewswire March 11, 2020

Spero Therapeutics Announces Closing of Rights Offering

GlobeNewswire March 5, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 28, 2020

Spero Therapeutics to Present at March Investor Conferences

GlobeNewswire February 26, 2020

Spero Therapeutics Announces Commencement of Rights Offering

GlobeNewswire February 11, 2020